Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …

FGFRs are receptor tyrosine kinases with a role in several biological processes, such as the
regulation of development and tissue repair. However, alterations in FGFRs 1–4, such as …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

The circadian rhythm is an evolutionarily conserved time-keeping system that comprises a
wide variety of processes including sleep–wake cycles, eating–fasting cycles, and activity …

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

Abstract Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …

Purpose: Medullary thyroid cancer (MTC) accounts for about 2% of all thyroid cancer, but
has a relatively poor prognosis compared with differentiated thyroid cancer. Anlotinib is a …

Data from observational studies indicate that both physical activity as well as exercise (ie,
structured physical activity) is associated with reductions in the risk of recurrence and cancer …

Background The efficacy and safety of multikinase inhibitor anlotinib have been confirmed in
the treatment of advanced non-small cell lung cancer (NSCLC). However, the direct …

Angiogenesis has an essential role in tumor growth and metastasis, and blocking this
pathway has been a successfully utilized strategy in the clinical treatment of cancer …